ClinicalTrials.gg
CompletedNCT06385158Updated May 8, 2025

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population

A Phase 1 interventional study of GS1-144 tablet in Vasomotor System; Labile and Healthy Volunteer, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral dose escalation of GS1-144 tablets and the effects of food on the pharmacokinetics of GS1-144 in a Chinese population

Read the detailed description

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and assessing the food effect in Part 2,and to assess the safety and tolerability of multiple ascending doses of GS1-144 in healthy postmenopausal female participants in Part 3.

02

Conditions studied

  • Vasomotor System; Labile
  • Healthy Volunteer
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At the time of signing the form (ICF):

Part 1and Part 2 only: healthy male and female subjects aged between 18 and 45 years inclusive; Part 3 only: healthy women aged between 40 and 65 years inclusive who have undergone natural menopause (natural menopause is defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review acceptable) or (no menses for 12 months and confirmed by FSH level ≥40 mlU/mL);

  • Body weight ≥ 50 kg (male), ≥ 45 kg (female) with a between 19.0 and 27.9 kg/m2 inclusive at screening
  • From signing the ICF to 1 month (female subjects) /3 months (male subjects and their female partners) after the end of the study, no family planning and egg/sperm donation plans, and effective methods (such as IUD, bilateral tubal/vasectomy, condom and safe period calculation, etc.) (applicable to Parts 1 and 2)' ' ● Volunteer to sign ICF and be able to understand and comply with the requirements of this study

Exclusion criteria

Exclusion Criteria:

Any known allergy to the components or analogues of the product, or those with an allergic constitution (such as allergy to two or more drugs or foods);

  • A history of currently suffering from any other cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal and/or other major diseases deemed by the investigator;
  • Known/confirmed history of ;
  • A history of epileptic seizure or increased risk of epileptic seizure, or subjects with a recent history (within six months prior to screening) of head trauma leading to loss of consciousness or concussion;
  • A history of currently suffering from hypothalamic dysfunction;
  • Significant acute/chronic infections within two weeks prior to dosing;
  • Undergone major surgical procedures (such as coronary artery bypass grafting, organ resection, gynecological surgery, etc.) within six months prior to screening or plan to undergo any surgery during the trial;
  • Participated in other clinical trials (except those who have not received any intervention) within 3 months prior to dosing, Or are participating in other clinical trials.
  • Have lost or donated more than 400 mL of blood within 3 months prior to screening;
  • Have taken any prescription/over-the-counter drugs or dietary supplements ,within 7 days prior to dosing or within 5 half-lives of the drug (whichever is longer);
  • Clinically significant abnormalities on physical examination or genitourinary ultrasound at the time of screening;
  • Clinically significant abnormalities in vital signs, where the criteria for clinically significant blood pressure abnormalities are defined as systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, and diastolic blood pressure ≥ 90 mmHg or \< 60 mmHg;
  • Prolonged interval in 12-lead results (> 450 ms for males, > 470 ms for females) or clinically significant abnormalities in other 12-lead ECG parameters at screening;
  • (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total (TBIL), blood creatinine (CRE), blood urea nitrogen (BUN), or (INR) higher than the (ULN) at screening, that are considered as clinically significant abnormalities by the investigator;
  • Part 3 only: abnormal sex hormone levels at screening that are considered clinically significant by the investigator;
  • Clinically significant abnormalities in thyroid function, parathyroid function, and neck ultrasound results at screening;
  • Women with positive pregnancy test result or those who are breastfeeding before dosing;
  • Positive virus antibody (HCV Ab), positive antibody (HIV Ab) or positive surface antigen (HbsAg) result at screening;
  • Unable to refrain from consuming grapefruit, pomelo, grapefruit juice, or pomelo juice from 7 days prior to dosing until the end of the study;
  • Unable to refrain from consuming any foods or beverages containing caffeine or xanthine (such as coffee, strong tea, chocolate, etc.) from 7 days prior to dosing until the end of the study;
  • Unable to abstain from smoking/using tobacco products from 7 days prior to dosing until the end of the study, or positive urine cotinine test result before dosing
  • Unable to refrain from consuming alcohol from 7 days prior to dosing until the end of the study, or positive breath alcohol test result before dosing;
  • Any history of narcotic use or drug abuse, or positive urine drug screening result before dosing;
  • Any medical or other condition, in the opinion of the investigator, may affect the clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    GS1-144 tablet

    Drug: GS1-144 tablet

  • Placebo comparator
    placebo controlled study

    Drug: GS1-144 tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1:Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of participants with TEAEs and SAEs will be reported

    Time frame: Up to Day 4

  2. Part 2: Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).

    Number of participants with TEAEs and SAEs will be reported.

    Time frame: Up to Day 9;

  3. Part 3: Number of Participants With TEAEs and SAEs

    Number of female post-menopausal participants with TEAEs and SAEs will be reported.

    Time frame: Up to Day 12

Secondary outcomes

  1. Part1,Part2 and Part3 AUC0-t- Area Under the Drug Concentration-time Curve From Time 0 to the Last Sample Collection Time t for GS1-144

    AUC0-t will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,

  2. Part 1 , Part2 and Part 3: AUC0-infinity- Area Under the Drug Concentration-time Curve From 0 to Infinity for GS1-144

    AUC0-infinity will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,

  3. Part 1, Part2 and Part 3: Cmax- Maximum Observed Plasma Concentration for GS1-144

    Cmax will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,

  4. Part 1 Part2 and Part 3: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for GS1-144

    Tmax will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose

  5. Part 1 Part2 and Part 3:: T1/2- Terminal Half-life for GS1-144

    T1/2 will be assessed and reported.

    Time frame: Time Frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  6. Part 1 Part2 and Part 3: CL/F- Apparent Clearance for GS1-144

    CL/F will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  7. Part 1 Part2 and Part 3: Vd/F- Apparent Volume of Distribution for GS1-144

    Vd/F will be assessed and reported.

    Time frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  8. Cmax,ss- Observed Maximum Concentration at Steady State for GS1-144

    Cmax at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  9. Part 3: Cmin,ss- Observed Minimum Concentration at Steady State for GS1-144

    Cmin at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  10. Part 3: Tmax,ss- Time of Cmax at Steady State for GS1-144

    Tmax at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  11. Part 3: Cavg,ss- Average Concentration at Steady State for GS1-144

    Cavg at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  12. Part 3: AUC0-τ- Area Under the Drug Concentration-time Curve During the Dosing Interval at Steady State for GS1-144

    AUC0-T at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  13. Part 3: CLss/F- CL for Bioavailability at Steady State for GS1-144

    CL/F at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 30 hour post-dose

  14. Part 3: T1/2,ss- Terminal Half-life at Steady State for GS1-144

    T1/2 at steady state will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  15. Part 3: Accumulation Ratio for GS1-144

    Accumulation Ratio will be assessed and reported.

    Time frame: Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose

  16. Part 1: Baseline and placebo-adjusted changes in ∆∆QTc and other ECG parameters after oral administration of GF1-144 in healthy subjects

    Time frame: Part 1 Day 1- pre-dose and up to 24 hour post-dose

07

Study locations

1 site
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai 200040, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jan 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 25, 2024
StartActual
Jan 3, 2024
Primary completionActual
Jan 6, 2024
CompletionActual
Nov 5, 2024
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06385158
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jan 3, 2024
Primary completion
Jan 6, 2024
Completion
Nov 5, 2024
Last update
May 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GS1-144

Start the discussion